logo

For the Inventor, By the Inventor

Houston, TX, United States of America

Michael A Tainsky

This inventor holds 4 USPTO granted patents. Top assignee: The University of Texas System. Active years: 2000-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael A Tainsky. Retrieved from https://idiyas.com/inventor/michael-a-tainsky-i9epl5lf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 43(Granted Patents)


Company Filing History:

goldMedal4 out of 5,638 
 
The University of Texas System
 patents

Years Active: 2000-2006

Loading Chart...
4 patents (USPTO):Explore Patents
1. 6998117 - Cancer treatment with retroviral vectors comprising wild-type p53 (2006-02-14),
2. 6627189 - Inhibition of cellular proliferation using ras antisense molecules (2003-09-30),
3. 6436700 - Anti-sense p21 k-ras (2002-08-20),
4. 6017524 - Inhibiting the growth p53 deficient tumor cells by administering the p53 (2000-01-25),

Title: Michael A Tainsky: Innovator in Cancer Treatment

Introduction

Michael A Tainsky is a prominent inventor based in Houston, TX (US), known for his significant contributions to cancer treatment research. With a total of 4 patents, Tainsky has focused on innovative methods to manipulate gene expression, particularly in the context of cancer therapies.

Latest Patents

Tainsky's latest patents include groundbreaking work on cancer treatment using retroviral vectors that comprise wild-type p53. These patents disclose methods and compositions for selectively manipulating gene expression through retroviral expression vectors. The vectors are designed to express antisense sequences, such as K-ras oncogene antisense sequences, or sequences encoding desired products like wild-type p53 sequences. A notable embodiment of his work involved transfecting a human lung cancer cell line (NCI-H460a) with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. This innovative approach led to a three-fold growth inhibition in H460a cells, demonstrating the potential of antisense RNA technology in cancer treatment.

Career Highlights

Tainsky is affiliated with the University of Texas System, where he continues to advance research in cancer therapies. His work has garnered attention for its potential to significantly impact the field of oncology.

Collaborations

Some of Tainsky's notable collaborators include Jack A Roth and Tapas Mukopadhyay, who have contributed to the development of his innovative cancer treatment methodologies.

Conclusion

Michael A Tainsky's work exemplifies the intersection of innovation and medical research, particularly in the fight against cancer. His patents reflect a commitment to advancing therapeutic strategies that could change the landscape of cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…